Drug repurposing study finds lonafarnib effective against RSV

A study in Nature Communications identifies lonafarnib from the ReFRAME drug-repurposing library as a potent inhibitor of the RSV fusion protein, showing promise in reducing RSV infection in vitro and in vivo.

H1 Launches H1 Connect: Matching Doctors with Global Health Missions

What You Should Know: H1, the leading platform for global healthcare data with a database of 10M+ healthcare professional profiles, today announced a new module within

April 4, 2024

New guidelines for conducting systematic reviews of animal and cell studies

A new publication in Nature Reviews Methods Primers provides essential guidance for conducting rigorous systematic reviews on studies with animals and cells.

October 3, 2024

Aspirin for CRC Risk Reduction May Benefit Unhealthy People Most

Regular aspirin use was associated with a reduced risk of colorectal cancer (CRC) among individuals with less healthy lifestyles, according to results from a prospective

August 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.